<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Multiplex reverse transcription-polymerase chain reaction (M-RT-PCR) has been proved to possess great clinical potential for simultaneous screening of 29 chromosomal translocations in <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>To evaluate the clinical value of M-RT-PCR in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, bone marrow samples from 90 patients with various <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, including 25 <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 22 <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL), 27 <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), 4 <z:mpath ids='MPATH_512'>myeloproliferative diseases</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>), 3 <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (CLL), 3 non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), 3 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), 2 <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) and 1 malignant histocytosis (MH) were subjected to both M-RT-PCR and chromosome karyotypic analysis </plain></SENT>
<SENT sid="2" pm="."><plain>Some of cases were subjected to follow-up examination of M-RT-PCR during the period of clinical complete remission (CR) for detection of minimal residual <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>In our hand, 12 of 29 chromosomal translocation transcripts including <z:chebi fb="18" ids="30182">TEL</z:chebi>/PDGFR, DEK/CAN, MLL/AF6, AML1/<z:chebi fb="0" ids="27561">ETO</z:chebi>, MLL/AF9, BCR/ABL, MLL/MLL, PML/RARu, TLS/ERG, E2A/HLF, EVI1 and HOXI1 were detected in 57 cases (63.3 %) of the 90 samples, which were in consistence with the results of karyotypic analysis </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, M-RT-PCR had also shown good clinical relevance when used as an approach to detect minimal residual <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>We concluded that M-RT-PCR could be used as an efficient and fast diagnostic tool not only in the initial diagnosis of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> but also in subsequent monitor of minimal residual <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
</text></document>